EverSource Wealth Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

EverSource Wealth Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$674K	Sell	1,357 -150	-10%	-$66.5K	0.02%	457
2026 Q1	$672K	Buy	1,507 +416	+38%	+$194K	0.02%	489
2025 Q4	$494K	Buy	1,091 +159	+17%	+$68.5K	0.02%	546
2025 Q3	$365K	Sell	932 -14	-1%	-$5.85K	0.01%	625
2025 Q2	$421K	Buy	946 +380	+67%	+$175K	0.02%	522
2025 Q1	$274K	Buy	566 +161	+40%	+$75K	0.02%	554
2024 Q4	$163K	Sell	405 -28	-6%	-$13K	0.01%	728
2024 Q3	$201K	Sell	433 -165	-28%	-$79.3K	0.01%	553
2024 Q2	$296K	Buy	598 +33	+6%	+$14.3K	0.02%	442
2024 Q1	$222K	Buy	565 +9	+2%	+$3.81K	0.02%	456
2023 Q4	$226K	Buy	556 +2	+0.4%	+$739	0.02%	403
2023 Q3	$193K	Buy	554 +15	+3%	+$5.25K	0.02%	405
2023 Q2	$190K	Sell	539 -46	-8%	-$15.5K	0.02%	407
2023 Q1	$184K	Sell	585 -4	-0.7%	-$1.2K	0.02%	383
2022 Q4	$170K	Sell	589 -7	-1%	-$2.13K	0.03%	375
2022 Q3	$172K	Buy	596 +171	+40%	+$49.2K	0.04%	322
2022 Q2	$120K	Buy	425 +268	+171%	+$71.7K	0.03%	336
2022 Q1	$41K	Sell	157 -5	-3%	-$1.19K	0.01%	503
2021 Q4	$35K	Buy	+162	New	+$31.5K	0.01%	495

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

EverSource Wealth Advisors's VRTX Position: Q2 2026 in Review

EverSource Wealth Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 10% in Q2 2026, selling an estimated $66.5K and leaving 1,357 shares worth $674K. The position accounts for 0.02% of the portfolio, ranked #457.

EverSource Wealth Advisors first reported a position in VRTX in Q4 2021 and has held it in 19 quarters since. 1,749 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

EverSource Wealth Advisors held 1,357 shares of Vertex Pharmaceuticals worth $674K as of Q2 2026.
EverSource Wealth Advisors sold 150 Vertex Pharmaceuticals shares in Q2 2026, an estimated $66.5K.
Vertex Pharmaceuticals made up 0.02% of EverSource Wealth Advisors's portfolio in Q2 2026, its #457 holding.
EverSource Wealth Advisors first reported a position in Vertex Pharmaceuticals in Q4 2021 and has held it in 19 quarters since.
1,749 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.